Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

A new study published in the Journal of Alzheimer’s Disease suggests that vortioxetine, an antidepressant with a unique multimodal mechanism, may offer greater benefits for both mood and cognitive ...

Researchers find that tiny doses of lithium could slow Alzheimer’s symptoms by reducing brain plaques and protecting neural ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

People with Alzheimer’s disease have lower levels of lithium in their brains than those without cognitive impairment, and the ...

Groundbreaking new Alzheimer’s treatment could give patients four years of better health. Patients who participated in the ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.